ClinicalTrials.gg
Not yet recruitingNCT07660510CAPSASENSUpdated Nov 13, 2026

Evolution of Different Sensitivity Levels in Patients With Chronic Neuropathic Pain in the Pelvi-perineal Region After Treatment With High-concentration Capsaicin Patches

An interventional study of Quantitative Sensory Testing and questionnaires in Neuropathic Pain and Nociplastic Pain, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other

How we know

Updated Nov 13, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Neuralgia with a site in France — 39 open to participants now, 40 under way, 4 of them phase 3. Neuralgia · France.

Planned enrollment
79th of 102
30 · median 62
Started
2026
with 10 others
No phase
46 of 132
23 open now
Primary completion
2028-03
later than 26 of 39 live
Registered
129th of 132
by date
Lead sponsor
6 of 132
Nantes University Hospital

Among the 132 studies in Neuralgia with a site in France, this one is the 79th largest by planned enrollment of the 102 interventional ones that give a count, is one of 11 that started in 2026, is one of 46 with no phase, reaches primary completion later than 26 of the 39 other live ones, and was the 129th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

39 of the 132 studies in Neuralgia with a site in France are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Neuralgia with a site in France, or all of them as a file.
02

Study summary

The primary objective of this study will be to demonstrate a change in pain sensitization parameters before and after the application of the high-concentration capsaicin patch.

Read the detailed description

Category 2 Study (Interventional Research with Minimal Risks and Constraints), monocentric, uncontrolled, non-randomized, open-label and prospective.

This study involves conducting tests and questionnaires before and 1 month after the application of a patch administered as part of standard clinical practice.

03

Conditions studied

  • Neuropathic Pain
  • Nociplastic Pain

Keywords

  • Sensitization
  • 8% capsaicin patch
  • Quantitative Sensory Testing
  • Temporal Summation
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥ 18 years old.
  • Patients suffering from chronic pelvi-perineal neuralgia (>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC).
  • Patient who has never been treated with an 8% capsaicin patch for this indication.
  • Patients who have signed the form for the study at the inclusion visit.
  • Women must meet one of the following criteria at the time of inclusion:
  • Use adequate measures;
  • or Be (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments);
  • or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels;
  • or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients under guardianship, curatorship, or legal protection.
  • Pregnant or breastfeeding women.
  • Patients with to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, to any of its components.
  • Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation).
  • Patients not affiliated with the French Social Security system.
  • Patients with insufficient cooperation and/or understanding to strictly comply with the protocol requirements.
  • Patients who have taken analgesics within the 12 hours prior to measurements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pain sensitization parameter testing

    Pre-inclusion visit (routine care consultation): Verification of inclusion and exclusion criteria. Inclusion visit (Day 0): Consent signing, questionnaires (ConvergencePP Score/Central Sensitization Inventory, DN4), and a series of tests, followed by the application of the high-concentration capsaicin patch (PCHC) (performed during routine care). Day 30 visit (+7 days): Questionnaires (same as V1 + PGI-c) and a series of tests.

    Other: Quantitative Sensory Testing and questionnaires

Interventions

  • OtherQuantitative Sensory Testing and questionnaires

    Quantitative Sensory Testing and questionnaires

06

What researchers measure

Primary outcomes

  1. Composite criterion

    Composite criterion constructed from a Principal Component Analysis including the differences between Day 0 (before patch application) and Day 30 in pain perception thresholds (to cold, heat, pressure, and mechanical stimulation) in both the area treated with the high-concentration capsaicin patch and the corresponding dermatome, as well as the change in the pain receptive field area in the treated zone and the area under the curve of temporal summation measurements.

    Time frame: Difference between Day 0 and Day 30

Secondary outcomes

  1. Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (1)

    Difference in pressure pain thresholds in the treated area

    Time frame: Between before and 30 days after patch application

  2. Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (2)

    Difference in mechanical stimulation pain thresholds

    Time frame: Between before and 30 days after patch application

  3. Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (3)

    Difference in cold pain thresholds in the treated area

    Time frame: Between before and 30 days after patch application

  4. Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (4)

    Difference in heat pain thresholds in the treated area

    Time frame: Between before and 30 days after patch application

  5. Measure the effect of the high-concentration capsaicin patch on peripheral sensitization (5)

    Difference in pain receptive field area

    Time frame: Between before and 30 days after patch application

  6. Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (1)

    Difference in pressure pain thresholds in an area of the dermatome not directly treated by the patch: * Ipsilateral retro-malleolar groove (S2 root) for inferior cluneal nerve neuralgia treatment, * Posterior iliac crest relief, 7 cm from the midline (L1) for ilio-inguinal or ilio-hypogastric neuralgia treatment, * Perineal body (S4) for sacrococcygeal plexus neuralgia treatment.

    Time frame: Between before and 1 month after patch application.

  7. Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (2)

    Difference in mechanical stimulation pain thresholds in an area of the dermatome not directly treated by the patch

    Time frame: Between before and 1 month after patch application.

  8. Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (3)

    Difference in cold pain thresholds in an area of the dermatome not directly treated by the patch.

    Time frame: Between before and 1 month after patch application.

  9. Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (4)

    Difference in heat pain thresholds in an area of the dermatome not directly treated by the patch.

    Time frame: Between before and 1 month after patch application.

  10. Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (5)

    Difference in the area under the curve of temporal summation measurements in the treated area

    Time frame: Between before and 1 month after patch application.

  11. Measure the effect of the high-concentration capsaicin patch (PCHC) on spinal sensitization (6)

    Difference in the duration of pain persistence after the end of temporal summation (in seconds).

    Time frame: Between before and 1 month after patch application.

  12. Measure the patient's therapeutic response to the treatment

    Patient Global Impression of Change (PGI-C). The therapeutic response is defined as a patient who scores 1 to 3 on the PGI-C.

    Time frame: Day 30

  13. Evaluate the predictive value of temporal summation with regard to the therapeutic response to the high-concentration capsaicin patch

    Investigation of a relevant threshold for temporal summation to predict the therapeutic response. Quantification of the positive predictive value.

    Time frame: Between before and 1 month after patch application.

  14. Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data

    Measure the correlation between Convergences PP scores, CSI, and semi-objective sensitization data. The Convergences PP score is a clinical questionnaire used to diagnose sensitization in the pelvic region. A score is considered positive from 5/10 (sensitivity = 95%, specificity = 87%). The Central Sensitization Inventory (CSI) is a self-administered questionnaire used to diagnose central sensitization. A score is considered positive from 40/100. Correlations between the Convergences PP score, CSI, and semi-objective sensitization data (pain thresholds and temporal summation) will be measured using Spearman's correlation coefficient to explore the relationships between these variables.

    Time frame: Between before and 1 month after patch application

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2028, 15 months later.

Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 15 months is below that.

Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartEst.
Nov 20, 2026was Sep 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Nov 20, 2026
Nov 13, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedPatient who has never been treated with an 8% capsaicin patch for this indication.
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Sep 1, 2026→Nov 20, 2026
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedPatient who has never been treated with an 8% capsaicin patch for this indication.
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07660510
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Amélie LEVESQUE, MD
Contact
amelie.levesque@chu-nantes.fr
+33240083912

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion